Skip to Content

Naltrexone / oxycodone Pregnancy and Breastfeeding Warnings

Naltrexone / oxycodone is also known as: Troxyca ER

Naltrexone / oxycodone Pregnancy Warnings

Advise pregnant women of the potential risk to fetus US FDA pregnancy category: Not assigned Risk Summary: Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal; there are no available data to inform a drug-associated risk for major birth defects and miscarriage. Comments: -Pregnant women should be advised of the risk of neonatal abstinence syndrome and ensure that appropriate treatment will be available. -Naltrexone may precipitate withdrawal in the fetus due to the immaturity of the fetal blood-brain barrier. -Long-acting opioids should not be used during and immediately prior to labor, when short acting analgesics or other analgesic techniques are more appropriate.

Animal studies with immediate-release oxycodone during organogenesis have not revealed evidence of teratogenicity or embryo-fetal toxicity; however published studies have shown neurobehavioral effects in rat pups at clinically relevant doses. Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. During clinical trials, plasma naltrexone levels were detectable in some patients receiving this combination drug, therefore, there is a possibility that naltrexone could precipitate withdrawal in a fetus due to the immaturity of the fetal blood-brain barrier. There are no adequate well-controlled studies with this combination drug in human pregnancies. Chronic opioid use may cause reduced fertility in males and females; it is not known whether these effects are reversible. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Naltrexone / oxycodone Breastfeeding Warnings

Lactation studies are not available with this combination drug. Published information on immediate-release oxycodone has shown infant sedation is common. During clinical trials, plasma naltrexone levels were detectable in some patients receiving this combination drug and therefore, it may be possible that naltrexone could precipitate withdrawal in a breastfed infant.

Use is not recommended Excreted into human milk: Yes (oxycodone); Yes (naltrexone) Comments: -Breastfed infants should be closely monitored for excess sedation and respiratory depression; prompt medical attention should be obtained if trouble breathing, increased sleepiness, difficulty breastfeeding, or limpness develops. -Withdrawal symptoms may occur in breastfed infants when maternal administration is stopped or when breastfeeding is stopped.

See references

References for pregnancy information

  1. "Product Information. Troxyca ER (naltrexone-oxyCODONE)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

References for breastfeeding information

  1. "Product Information. Troxyca ER (naltrexone-oxyCODONE)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide